Jiangsu Hengrui Medicine Co., Ltd.

This study tests a new drug called SHR-A1904 in people with advanced solid tumors, specifically stomach or pancreatic cancer that has not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 83 adults will take part in th…

This study tests a new drug called HRS-4508 combined with other cancer treatments for people with advanced non-small cell lung cancer that has stopped responding to standard therapy. About 100 adults aged 18-75 will participate to find the best dose, check safety, and measure how…

This study tests a new drug (HRS-1167) combined with two standard treatments (abiraterone and prednisone) in 66 men with metastatic prostate cancer. The goal is to find the safest dose and see if the combo works better at controlling the disease. Participants must have advanced c…

This early-stage study tests a new drug called HRS-2329 in people with advanced solid tumors that have RAS gene mutations or amplifications. The main goals are to check safety, find the best dose, and see how the drug moves through the body. About 120 adults who have already trie…

This phase 3 trial tests a new drug called SHR-A1811 against standard chemotherapy in 300 people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatment. The goal is to see if the new drug can slow cancer growth and improve s…

This study tests a new drug, SHR2554, combined with other cancer treatments for people with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and shrinks tumors. About 200 adults aged 18-75 with good…

This study tests a new drug, Trastuzumab Rezetecan, against an existing one, Trastuzumab Deruxtecan, in 150 women with advanced breast cancer that is HR-positive and HER2-low. Participants must have already tried hormone therapy without success. The goal is to see which dose work…

This study tests a new drug called SHR-A1811 in 60 women with HER2-positive cervical cancer that has come back or spread and no longer responds to standard therapy. The drug targets cancer cells with HER2 protein to shrink tumors. The goal is to see how many patients respond and …

This study tests a new drug called SHR-A1811 against a standard chemotherapy combination for people with early-stage or locally advanced HER2-positive breast cancer. About 740 women will receive either the new drug or standard treatment before surgery. The goal is to see if the n…

This study is testing a new drug called SHR-4394 combined with other anti-cancer treatments for men with prostate cancer. The goal is to find the safest dose and see if the combination can lower PSA levels, a key marker of prostate cancer. About 100 men aged 18 to 85 will take pa…

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This early-phase study tests an experimental drug called SHR-1049 in 200 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants receive the…

This study tests a new drug, SHR-A1811, against standard treatments for people with advanced or metastatic non-small cell lung cancer that has a specific change in the HER2 gene. About 300 participants who have not had prior treatment for advanced disease will be enrolled. The go…

This study tests two experimental drugs (HS-20093 or SHR2554) given together with standard hormone therapy in men with metastatic prostate cancer. The goal is to see if the combinations are safe and help lower PSA levels, a marker of cancer activity. About 218 men aged 18 to 80 w…

This phase 3 trial tests whether a radioactive drug (lutetium-177) plus standard-dose octreotide works better than high-dose octreotide alone for people with advanced gastrointestinal or pancreatic neuroendocrine tumors. The study involves 220 adults aged 18-75 with tumors that c…

This study tests a new drug, SHR2554, against an existing drug, chidamide, in people with a rare blood cancer called peripheral T-cell lymphoma (PTCL) that has returned or not responded to prior therapy. About 130 adults aged 18-70 will be randomly assigned to one of the two trea…

This study tests a new drug called HRS-6209 given with other treatments for breast cancer. About 80 women aged 18-75 whose cancer has worsened after prior therapy will take part. The goal is to find safe doses and see if the combination can shrink tumors.

This study tests a drug called herombopag in people with chronic liver disease who have low platelet counts and need surgery. The goal is to see if the drug can safely raise platelet levels enough to reduce bleeding risk during the procedure. About 101 adults with mild to moderat…

This study tests whether adding a new drug (SHR4640) to a standard gout medication (febuxostat) works better than just increasing the dose of febuxostat alone. About 340 adults with gout and high uric acid who are not well-controlled on 40 mg of febuxostat will take either the co…

This early-stage study tests an experimental drug called HRS-6093 in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. About 153 adults aged 18-75 who have ex…

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This early-stage study tests a new drug, HRS-3005, in 190 adults with B-cell blood cancers that have returned or not responded to prior treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be in fairly go…

This study tests a new drug called HRS-4642 combined with other cancer treatments in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to find the safest dose and see if the combination can shrink tumors. About 118 adults aged 18-75 wi…

This study tests two different drug combinations for people with advanced HER2-positive non-small cell lung cancer. The goal is to see if these combos can shrink tumors and control the disease. About 324 adults aged 18-75 with good performance status are being enrolled. This is a…

This study tests a new drug called FH-006 in 200 women with advanced solid tumors that have worsened after standard treatments. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants will be closely monitored for side effects and immune …

This study tests a new drug called HRS-6768 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can help control the disease. About 84 participants will take part in this early-phase trial.

This study tests a new drug, HRS-9190, against a standard muscle relaxant used during surgery. About 60 adults having planned surgery will get one of the two drugs. The main goal is to see how fast muscles recover after the drug is stopped. Researchers will also check for side ef…

This early-stage study tests a new drug called HRS-7172 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check safety, find the best dose, and see how the body processes the drug. About 120 adults aged 18-75 with good organ fun…

This study tests a new drug, HRS-4357, against current standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will enroll 370 men and measure how long the cancer stays under control. The go…

This study tests a new drug called HRS-4508 in people with advanced non-small cell lung cancer that has stopped responding to standard treatments. About 120 adults aged 18 to 80 will receive the drug to see if it shrinks tumors and how safe it is. The goal is to control the disea…

This study tests a new drug called SHR2554 combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and helps shrink tumors. About 351 …

This study tests a new drug called FH-006 given alongside other cancer treatments for people with advanced non-small cell lung cancer. The goal is to find the safest dose and see if it helps shrink tumors. About 200 adults aged 18 to 75 who cannot have surgery or radiation are be…

This phase 3 study tests whether a new drug, rezvilutamide, works better than the standard drug enzalutamide for men with low-volume metastatic hormone-sensitive prostate cancer. Both drugs are combined with hormone therapy (ADT). The study aims to see which treatment lowers PSA …

This early-stage study is testing a new injectable drug called SHR-3167 in 55 adults with type 2 diabetes. The goal is to understand how the drug moves through the body and how it affects blood sugar levels. Participants will receive the drug and be monitored for side effects and…

This phase 3 trial tests a new combination of drugs (irinotecan liposome, oxaliplatin, 5-FU, and calcium folinate) against a standard combination (nab-paclitaxel and gemcitabine) as the first treatment for people with metastatic pancreatic cancer. The study will enroll about 662 …

This study tests a new sedative drug called tegileridine fumarate in 120 ICU patients who need a breathing machine for 2-3 days. The goal is to see if it keeps patients calm and comfortable better than current options. Participants are adults aged 18-85 who recently started on a …

This study tests a long-acting painkiller (bupivacaine liposome) injected near the spine to control pain after chest surgery. About 96 adults having lung removal through a single small cut will receive either the study drug or a standard painkiller. The goal is to see if it reduc…

This study looks at a painkiller called bupivacaine liposome injection, given during surgery to help control pain afterward. It involves 232 children aged 6 to 17 having orthopedic (bone) surgery. The goal is to see if it safely reduces pain and the need for stronger opioid pain …

This early-stage study tests different doses of an experimental diabetes drug called SHR-3167 in 60 healthy adults aged 18 to 55. The goal is to measure how much of the drug gets into the blood and how safe it is, not to treat any disease. Participants will receive a single injec…

This early-stage study tests the safety and tolerability of a new injectable drug called HRS-2183 in 42 healthy Chinese adults aged 18-45. Participants receive either a single dose or multiple doses to see how the drug moves through the body and if it causes any side effects. Thi…